Healthcare Professionals

Committed to helping you meet the evolving challenges and opportunities in patient care.

Healthcare Professionals
  • Primary Care

    Supporting every aspect of your clinical practice, including physical exam, diagnostic cardiology, vitals monitoring and vision screening

  • Hospital Care

    Advancing products and technologies designed to speed patient recovery and streamline clinical workflows

  • Surgical Care

    Delivering innovations that enable reduced operating times, faster patient recovery and improved outcomes

  • Kidney Care

    Pioneering care in hemodialysis (HD), peritoneal dialysis (PD) and digital health to support better outcomes for your patients

  • Nutritional Care

    Personalizing nutritional care designed to improve patients’ health in the hospital, the ICU and at home

  • Respiratory Care

    Helping your patients with respiratory therapies designed to simplify delivery and improve mobility

  • Our Products

    Our portfolio of acute, nutritional, renal, hospital and surgical care products helps advance healthcare around the world.

Perspectives

For nearly a century, we have worked at the intersection of saving and sustaining lives.

Perspectives

Our Story

Our 90-year heritage gives us distinct perspective on the needs of patients and caregivers. We lead today by putting those insights to work to deliver new, better healthcare solutions and access to care in the communities where we live and work.

Our Story
  • Our Leadership

    Our forward-looking leadership team is a driving force in ensuring we meet the needs of all our stakeholders – every day and everywhere.

  • Our Governance

    We are proud of our strong commitment to maintaining the highest standards of corporate governance.

  • Fueling Collaborative Innovation

    Nurturing a culture of innovation is critical to delivering on our mission to save and sustain lives. We partner with the healthcare community to continually find more efficient, smarter ways to help solve the world's most pressing healthcare challenges.

  • Corporate Responsibility

    We strive to create lasting value by empowering our patients, protecting our planet and championing our people and communities.

  • Diversity, Equity & Inclusion

    We are committed to attracting, motivating and retaining an inclusive and diverse workforce.

  • Our History

    For nearly a century, we’ve been focused on saving and sustaining lives and elevating patient care.

Patients

Helping you reach a healthy life, full of possibility.

Patients
  • General Healthcare

    Whether you are receiving care in the hospital, at your doctor’s office or at home, we are here to support every step of your journey.

  • Nutritional Care

    When medical conditions prevent you from adequately feeding yourself, we provide life-saving clinical nutrition options to help you regain your nutritional status.

  • Kidney Care

    Kidney disease is an ongoing journey for you and your family. While every journey is unique, Baxter is committed to supporting access to care options to meet your medical and lifestyle needs.

  • Respiratory Care

    We are committed to helping you with innovative products that deliver effective, proven respiratory therapy in the hospital and at home.

Search Results

2019 First Quarter Financial Results Thumbnail

Baxter Reports First-Quarter 2019 Results

Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the first quarter of 2019 and increased its full-year 2019 earnings outlook.

Baxter Unveils the Latest Evolution of Floseal at AORN Meeting

Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, today announced that it has received U.S. Food and Drug Administration (FDA) approval for faster preparation of its leading hemostatic product, Floseal Hemostatic Matrix, at the 2019 Association of periOperative Registered Nurses (AORN) Global Surgical Conference and Expo.

4Q & FY 2018 Financial Results Thumbnail

Baxter Reports 2018 Fourth-Quarter and Full-Year Results

Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the fourth quarter and full year ended Dec. 31, 2018, and provided its financial guidance for 2019.

Baxter Launches Curved Applicator for Floseal, Expanding Use of Leading Hemostat During ENT Procedures

Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, today announced the introduction of the Disposable Curved Applicator, which enhances the delivery experience of its Floseal Hemostatic Matrix product line for procedures in the otolaryngology, head and neck surgical specialty (often referred to as ENT).

Baxter Unveils New Products at the ASMBS – Obesity Week Meeting to Help Surgeons Overcome Challenges During Bariatric Surgery

Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, revealed its Peri-Strips Dry with Veritas (PSDV) Circular Staple Line Reinforcement with Secure Grip technology, the latest evolution in a product portfolio that has more than 20 years of proven clinical use in surgical buttressing and soft tissue repair.

Baxter Highlights Data at ISPOR Europe 2018 on Clinical and Economic Benefits When Addressing Malnutrition, Intraoperative Bleeding

Baxter International Inc. (NYSE:BAX), a leading global medical products company, is presenting four health economics and outcomes research (HEOR) analyses this week at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2018 meeting. The studies evaluated potential clinical and economic impacts of various products and practices associated with malnutrition and surgical procedures.

Baxter Introduces New Tisseel Prima Syringe at 2018 American Association of Gynecologic Laparoscopists Meeting

Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, today unveiled the latest design enhancements for its fibrin sealant product, the Tisseel Prima syringe, at the 2018 American Association of Gynecologic Laparoscopists (AAGL) meeting.

New Data on Floseal Surgical Hemostat Quantifies Clinical and Healthcare Resource Outcomes in Spine Surgery Cases

Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, announced the publication of two new analyses of real-world data regarding the use of Floseal Hemostatic Matrix in spinal surgeries. The retrospective studies observed better clinical and resource use outcomes in cases with billed charges for Floseal, when compared to cases with charges for Floseal in addition to certain non-flowable hemostatic agents.

Baxter Announces U.S. FDA Clearance of Altapore Bioactive Bone Graft in Posterolateral Spine Surgery

Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, today announced U.S. Food and Drug Administration (FDA) clearance of ALTAPORE Bioactive Bone Graft, a next-generation bioactive and osteoconductive bone graft substitute, for use as an autograft extender in posterolateral spinal fusion. ALTAPORE had previously been cleared for use in orthopedic surgical procedures in the extremities and pelvis.

Baxter Highlights Business Strategies and Innovation at 2018 Investor Conference

Baxter International Inc. (NYSE: BAX), today at its investor conference, outlined the company’s strategies to drive sustained growth, deliver attractive shareholder value and advance patient care around the world. Baxter defined its top-quartile goals around four key areas: patient safety and quality; growth through innovation; best place to work; and industry-leading performance; and its leadership team highlighted strategic growth opportunities across its six global businesses.